Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405681 | 0.91 | GCK (0.40) | LMNAGCKKMT2ARAB9ANPC1 | |
| SCHEMBL4445539 | 0.83 | NPC1 (0.36) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL1679369 | 0.82 | LMNA (0.38) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL19209537 | 0.81 | APOBEC3G (0.40) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL28514925 | 0.80 | LMNA (0.45) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL43414 | 0.80 | POLB (0.41) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL237958 | 0.77 | POLB (0.54) | LMNAKMT2ARAB9ANPC1POLB | |
| SCHEMBL7112244 | 0.76 | EHMT2 (0.35) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL12092095 | 0.76 | LMNA (0.42) | LMNAEHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL278281 | 0.75 | LMNA (0.39) | LMNAGCKKMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942996-B8 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | UNIV SOUTHERN CALIFORNIA (US) | 2007-02-21 | — | — | EP | claimed |
| EP-0942996-A1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | Diatide, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998024917-A1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | DIATIDE, INC. (US) | 1998-06-11 | — | — | WO | claimed |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-05-26 | — | — | US | disclosed |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3827844-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | Psma Development Company, L.L.C. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| EP-3057614-B1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | PSMA DEV COMPANY L L C (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-2673293-B1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | HARVARD COLLEGE (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10309973-B2 | Surrogates of post-translationally modified proteins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-06-04 | — | — | US | disclosed |
| US-5753204-A | IMAGING ANTIGENS, POLYPEPTIDES AND BINDING | CHIRON CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997025071-A9 | IMMUNOCONJUGATE FOR THE TREATMENT OF AIDS | — | 1997-11-13 | — | — | WO | disclosed |
| WO-1997025071-A2 | IMMUNOCONJUGATE FOR THE TREATMENT OF AIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-07-17 | — | — | WO | disclosed |
| EP-0776338-A1 | IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5587459-A | LINKED TO A LIGAND TARGETING A CELL SURFACE RECEPTOR; FOR TREATING CANCERS AND AUTOIMMUNE DISEASES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-12-24 | — | — | US | disclosed |
| WO-1996006116-A9 | IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS | — | 1996-03-28 | — | — | WO | disclosed |
| WO-1996006116-A1 | IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0688327-A1 | ANALOGS FOR SPECIFIC OLIGOSACCHARIDE-PROTEIN INTERACTIONS AND USES THEREFOR | Glycan Pharmaceuticals, Inc. (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020512-A2 | ANALOGS FOR SPECIFIC OLIGOSACCHARIDE-PROTEIN INTERACTIONS AND USES THEREFOR | GLYCAN PHARMACEUTICALS, INC. (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | LMNA 140/4885EHMT2 3427/4885EHMT1 2980/4885 |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | LMNA 140/4885EHMT2 3427/4885EHMT1 2980/4885 |
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | FOLH1, PSMA3, PSMA2 | LMNA 2247/4885EHMT2 148/4885EHMT1 230/4885 |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | LMNA 140/4885EHMT2 3427/4885EHMT1 2980/4885 |
| US-10309973-B2 | Surrogates of post-translationally modified proteins and uses thereof | CD59, SIGLEC9, CD209 | LMNA 113/4885EHMT2 1620/4885EHMT1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.